Form 4: Akero CSO Exercises Options, Sells Shares

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, executed pre-planned stock option exercises and subsequent share sales on September 8, 2025.

Summary

• Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, Inc. (AKRO), engaged in transactions involving the company's common stock and stock options.
• Transactions occurred on September 8, 2025, under a Rule 10b5-1 trading plan established on August 12, 2024.
• Rolph exercised stock options to acquire a total of 12,500 shares of common stock, specifically 7,044 shares at $21.09, 5,161 shares at $6.364, and 295 shares at $28.35.
• Concurrently, Rolph sold a total of 12,500 shares of common stock, comprising 12,466 shares at a weighted-average price of $44.169 and 34 shares at $44.875.
• Following these transactions, Rolph's direct beneficial ownership of common stock is 167,124 shares.
• Remaining derivative securities include stock options to buy 389 shares at an exercise price of $21.09 and 62,445 shares at an exercise price of $28.35.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While an insider sale occurred, it was pre-planned under a 10b5-1 plan, which mitigates negative sentiment. The sale at a higher price than option exercise is a positive for the individual, but not necessarily for the stock's immediate outlook.

Positives

• The transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating a planned and not reactive sale.
• The sale price of common stock ($44.169 and $44.875) is significantly higher than the exercise prices of the options ($21.09, $6.364, $28.35), indicating a profitable transaction for the officer.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market, though the context of option exercise often mitigates this.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May observe an insider selling shares, which could be interpreted in various ways, though the 10b5-1 plan context suggests a routine event.

Key Dates

Recommendation

The filing details a routine, pre-planned insider transaction (option exercise and sale) under a Rule 10b5-1 plan. This type of transaction does not typically provide new fundamental information about the company's operations or future prospects that would warrant a change in investment recommendation. The sale is likely for personal financial planning rather than a reflection of management's view on the company's immediate future performance. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Akero Therapeutics, AKRO, Timothy Rolph, Chief Scientific Officer, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Equity Sales, Beneficial Ownership